Renal clear cell carcinoma is usually treated with radical kidney surgery, but kidney cancer has a high rate of metastasis through blood transport, with the possibility of metastasis in about 60% of patients. Cancer cells can metastasize to any site, with the highest chance of metastasis in lung and bone, which can reach 52% and 40%. Early-stage clear cell carcinoma can be treated by surgery alone. For patients with intermediate to advanced stage, cellular immunotherapy is recommended as adjuvant treatment after surgery, which can greatly reduce the chance of cancer metastasis. Common radiotherapy is very insensitive to clear cell carcinoma and has a lot of side effects. Adjuvant therapy is mostly based on traditional Chinese medicine, but it is not effective for patients with intermediate or advanced stage or metastasis. It is recommended that patients with clear cell carcinoma should undergo biologic therapy after surgery, and DC-CIK cell immunotherapy is the most commonly used treatment. It can further kill the invisible microscopic lesions and free cancer cells in the blood during surgery, consolidate the efficacy of surgery, help patients recover and strengthen the function of immune system after surgery, effectively inhibit the proliferation of cancer cells, and prevent the recurrence and metastasis of tumor through the regulation of immune mechanism. One week or so after surgery is the best time to use biological therapy in clinical practice, which can help recovery, kill residual cancer and prevent recurrence in one. The effect of surgery with biological therapy is excellent! There are clinical data proving that combining biological immunotherapy with surgery at Shanghai Cancer Biotherapy Center can effectively remove a large number of tiny cancer cells and metastatic lesions left by surgery, and directly remove free cancer cells in blood or lymphatic circulation to prevent tumor recurrence and metastasis, as well as improve patients’ anti-tumor immune function and effectively resist and avoid the incidence of various post-operative infections. For patients with metastasis, DC-CIK cellular immunotherapy is also a good choice to shrink the mass, inhibit the activity of tumor cells, and achieve long-term survival with tumor for larger metastases. The treatment of renal clear cell carcinoma is not very difficult as long as the patient adopts a suitable treatment method. Moreover, nowadays, our medical technology is advancing and biological therapy is very advanced, which is very helpful to patients’ condition. I believe that in the future, the treatment effect and survival rate of cancer will be even better and people will not talk about cancer anymore!